Breaking News

Astellas Adds Executives

May 5, 2014

Zeiher and Barrett to head Global Development and Medical Affairs

Bernhardt Zeiher, M.D. has been appointed executive vice president of Global Development at Astellas and Jeannette A. Barrett, Ph.D., has been named vice president and head of Medical Excellence, Global Medical Affairs.
Dr. Zeiher will be responsible for Global Development Operations and Global Clinical Pharmacology and Exploratory Development (GCPED), in addition to serving as therapeutic area head of Immunology, Infectious Disease, Transplant, Central Nervous System and Pain. He will continue to report to Dr. Sef Kurstjens, chief medical officer and president of Global Development. Dr. Zeiher has more than 15 years of experience in the pharma industry. Most recently he was vice president of the inflammation/immunology therapeutic area at Pfizer.

Dr. Barrett will be responsible for supporting medical affairs activities globally and providing the tools, processes, systems and infrastructure to ensure transparency, operational consistency, limit risk and improve compliance. Dr. Barrett will report to Dr. Charlotte Kremer, senior vice president and head, Global Medical Affairs. Dr. Barrett has more than 20 years of experience in the areas of medical affairs, regulatory affairs and drug safety having held leadership roles at several global pharmaceutical companies, including Pfizer, where she spent 16 years.
"Both Bernie and Jeannette's global experience, along with their pharmaceutical and clinical knowledge, make them perfect fits for Astellas," said Kurstjens. "We are delighted to be promoting Bernie and bringing Jeannette on to the Astellas team to further our mission of bringing important treatment options to patients."

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks